Page last updated: 2024-11-04

vorinostat and Nevus, Pigmented

vorinostat has been researched along with Nevus, Pigmented in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Nevus, Pigmented: A nevus containing melanin. The term is usually restricted to nevocytic nevi (round or oval collections of melanin-containing nevus cells occurring at the dermoepidermal junction of the skin or in the dermis proper) or moles, but may be applied to other pigmented nevi.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Basu, D1
Salgado, CM1
Bauer, B1
Hoehl, RM1
Moscinski, CN1
Schmitt, L1
Reyes-Múgica, M1

Other Studies

1 other study available for vorinostat and Nevus, Pigmented

ArticleYear
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi.
    Melanoma research, 2021, 08-01, Volume: 31, Issue:4

    Topics: Cell Death; Cell Differentiation; Child, Preschool; Histone Deacetylase Inhibitors; Humans; Infant;

2021